Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

WHAT IS TYVASO?

TYVASO is the first and only FDA-approved medication to treat PH-ILD. It can increase your ability to be active

PH-ILD can be difficult and disruptive. It causes you to feel fatigued and out of breath, and you may have trouble walking more than a short distance. Treating PH-ILD right away can be a step forward you take for your health—and may help you enjoy more of the moments that matter most.

TYVASO:

Delivers medicine directly to your lungs, where it’s needed

Helps keep the blood vessels in your lungs open so that your heart can pump blood more easily

Can increase your ability to be active while decreasing the chance of PH-ILD getting worse

See how TYVASO works.

To read more about TYVASO, download the TYVASO Patient Brochure.

NOW APPROVED—TYVASO DPI FITS IN THE PALM OF YOUR HAND

Ask your healthcare provider about the
Dry Powder Inhaler (DPI) option now approved for TYVASO®.

bubbles pattern
hand holding dpi devicebubbles pattern

See how simple TYVASO DPI is to use.

bubbles pattern